Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - naltrexone hydrochloride, quantity: 50 mg - tablet, film coated - excipient ingredients: titanium dioxide; powdered cellulose; lactose monohydrate; microcrystalline cellulose; iron oxide black; crospovidone; iron oxide yellow; colloidal anhydrous silica; iron oxide red; hypromellose; macrogol 4000; magnesium stearate - naltrexone gh is indicated for use within a comprehensive treatment programme for alcohol dependence. naltrexone gh is also indicated as adjunctive therapy in the maintenance of formerly opioid-dependent patients who have ceased the use of opioids such as diamorphine (heroin) and morphine.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methylnaltrexone bromide, quantity: 12 mg - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; sodium calcium edetate; glycine hydrochloride; water for injections; sodium chloride - relistor is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care when response to laxative therapy has not been sufficient.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - naltrexone hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - naltrexone hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - naltrexone hydrochloride -

New Zealand - English - Medsafe (Medicines Safety Authority)

juno pharmaceuticals nz limited - morphine hydrochloride trihydrate 20 mg/ml equivalent to morphine base 15.18 mg/ml - solution for injection - 100 mg/5ml - active: morphine hydrochloride trihydrate 20 mg/ml equivalent to morphine base 15.18 mg/ml excipient: hydrochloric acid water for injection - morphine hydrochloride is indicated for: - the relief of moderate to severe pain not responsive to non-opioid analgesics - symptomatic relief of severe and intractable pains of various categories, in terminal cancer patients - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - ritonavir 100mg - film coated tablet - 100 mg - active: ritonavir 100mg excipient: calcium hydrogen phosphate colloidal silicon dioxide copovidone opadry white 16b18449 sodium stearyl fumarate sorbitan laurate - norvir is indicated for use in combination with appropriate antiretroviral agents or as monotherapy if combination therapy is inappropriate, for the treatment of hiv-1 infection in adults and children aged 12 years and older. for persons with advanced hiv disease, the indication for ritonavir is based on the results for one study that showed a reduction in both mortality and aids defining clinical events for patients who received ritonavir. median duration of follow-up in this study was 6 months. the clinical benefit from ritonavir for longer periods of treatment is unknown. for persons with less advanced disease, the indication is based on changes in surrogate markers in controlled trials of up to 16 weeks duration.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - oxycodone hydrochloride, quantity: 5 mg - tablet - excipient ingredients: microcrystalline cellulose; sodium starch glycollate type a; silicon dioxide; lactose monohydrate; maize starch; stearic acid - mayne pharma oxycodone ir is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; dilute hydrochloric acid - - short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. - symptomatic relief of severe and intractable pains in terminal cancer patients. - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: dilute hydrochloric acid; water for injections - - short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. - symptomatic relief of severe and intractable pains in terminal cancer patients. - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia.